News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
Break It Down
Break it Down: Tryptamine Therapeutics’ moves closer to IV-infused psilocybin treatment
Health & Biotech
‘Significant derisking catalyst’: Tryptamine’s world-first IV psilocin drug found safe
Health & Biotech
ASX innovators reshaping traditional medical treatments
Health & Biotech
Tryptamine completes world-first Phase 1b psilocin IV-infusion trial
Health & Biotech
How Tryptamine is pioneering precision psychedelic treatment
Long Shortz
Long Shortz with Tryptamine Therapeutics: Fantastic fibromyalgia results off the back of US psychedelic trial
Break It Down
Break it Down: Tryptamine Therapeutics reports positive results for Fibromyalgia patients
Health & Biotech
ASX Health Stocks: Psilocybin drug shows promise for fibromyalgia pain relief
News
Market Highlights: Wall Street surges as Big Tech blows through forecasts; and 5 ASX small caps to watch today
News
CLOSING BELL: Corruption? In Africa? Over mining licences? That can’t be right, surely…
News
CLOSING BELL: ‘How to falter at the last furlong and limp home like a beaten favourite’, by the ASX
News
ASX February Winners: Semiconductor stocks shine in tough month for investors
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Forcing the product to pay to be the product is about as Meta as it gets
News
ASX Small Caps Lunch Wrap: Who wants to watch China pull a CEO out of its hat today?
News
Rise and Shine: everything you need to know before the ASX opens
News
